Palisade Bio, Inc.
PALI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001357459
In the last 90 days, Palisade Bio, Inc. insiders filed 2 open-market purchases and 2 sales; 124 institutions reported holding it in 13F filings for Q2 2026, worth $362.4M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Palisade Bio, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 12 | 9 | −3 |
| Shares | 124.7K | 8.44K | −116.2K (−93.2%) |
| Value | $648.0K | $29.8K | −$618.2K (−95.4%) |
New holders (2)
Institutions that held Palisade Bio, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Tower Research Capital LLC (TRC) | 2,479 | $9.00K | 0.00% |
| Orion Capital Management LLC | 299 | $1.05K | 0.00% |
Sold out (5)
Institutions that held Palisade Bio, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| CVI Holdings, LLC | 40,000 | $208.0K |
| Warberg Asset Management LLC | 26,316 | $136.8K |
| Virtu Financial LLC | 20,461 | $106.0K |
| Two Sigma Securities, LLC | 19,692 | $102.4K |
| Two Sigma Investments, LP | 10,396 | $54.1K |